Covance Inc (CVD) 103.73 $CVD
Uptrend Call Working As Covance Stock Rises 29.5% (CVD)
Comtex SmarTrend(R) - Mon Dec 22, 9:14AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.08. In approximately 2 months, Covance has returned 29.49% as of today's recent price of $103.70.
CVD: 103.73 (+0.02)
Hart-Scott-Rodino Waiting Period Expires for LabCorp Acquisition of Covance
Business Wire - Tue Dec 16, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) and Covance Inc. (Covance) (NYSE: CVD) jointly announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with the previously announced merger agreement under which LabCorp will acquire all of the outstanding common stock of Covance. The waiting period expired on Monday, December 15.
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
27.3% Return Seen to Date on SmarTrend Covance Call (CVD)
Comtex SmarTrend(R) - Fri Dec 12, 4:46PM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 2 months, Covance has returned 27.29% as of today's recent price of $101.94.
CVD: 103.73 (+0.02)
COVANCE INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Fri Dec 12, 12:08PM CST
Rigrodsky & Long, P.A.:
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
LabCorp Buys DNA Testing Firm, Expands Forensics Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 1:00PM CST
Management at LabCorp (LH) is optimistic that this acquisition will enhance the company's range of forensics and DNA identification testing services.
ABC: 91.60 (+0.18), LH: 107.69 (+0.56), MMSI: 17.17 (+0.01), CVD: 103.73 (+0.02)
Investor Lawsuit Against Takeover of Covance Inc. (CVD) Announced by Shareholders Foundation
GlobeNewswire - Mon Dec 08, 9:15AM CST
The Shareholders Foundation, Inc. announces that an investor, who currently holds shares of Covance Inc. (CVD), filed a lawsuit in effort to stop the proposed takeover of Covance Inc. by Laboratory Corporation of America Holdings for a value of approximately $105.12 per CVD share.
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
Life Sciences Tools and Services Equities Coverage - Agilent Technologies, Thermo Fisher Scientific, Bruker, Quintiles Transnational, and Covance
PR Newswire - Mon Dec 08, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), Bruker Corporation (NASDAQ: BRKR), Quintiles Transnational Holdings Inc. (NYSE: Q), and Covance Inc. (NYSE: CVD). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 05, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,958.79, up 0.33% and the NASDAQ Composite closed at 4,780.76, up 0.24%. The S&P 500 finished the session 0.17% higher at 2,075.37. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 817.34, up 0.77%, with the index advancing 10.21% in the previous three months. Register for your complimentary reports on these five stocks at:
Q: 59.48 (+0.01), TMO: 126.79 (+0.13), A: 41.13 (-0.24), BRKR: 19.50 (+0.09), CVD: 103.73 (+0.02)
Watch Out: Barbarians At The Gate For Covance (CVD)
at The Street - Fri Nov 28, 9:15AM CST
Trade-Ideas LLC identified Covance (CVD) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CVD: 103.73 (+0.02)
Covance Has Returned 25.9% Since SmarTrend Recommendation (CVD)
Comtex SmarTrend(R) - Thu Nov 20, 11:02AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 4 weeks, Covance has returned 25.94% as of today's recent price of $100.86.
CVD: 103.73 (+0.02)
Morgan & Morgan Announces That It is Investigating the Sale of Covance, Inc. ? CVD
PR Newswire - Thu Nov 20, 10:15AM CST
Morgan & Morgan announces that it is investigating potential claims against the Board of Directors of Covance, Inc. ("Covance" or the "Company"
(NYSE: CVD) relating to the proposed acquisition by Laboratory Corporation of America Holdings ("LabCorp" .
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
Covance (CVD) Sellout Decision to LabCorp: A Strategic Fit? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:10PM CST
On Nov 18, we issued an updated research report on Covance Inc. (CVD).
Q: 59.48 (+0.01), LH: 107.69 (+0.56), SNY: 46.35 (+0.50), CVD: 103.73 (+0.02)
Earnings Look Back: Covance Is Down 0.3% Since Reporting Quarterly Results 2 Weeks Ago (CVD)
Comtex SmarTrend(R) - Mon Nov 17, 8:51AM CST
Two weeks ago on November 3rd, 2014 Covance (NYSE:CVD) reported earnings and analysts, on average, expected earnings of $0.98 on sales of $651.1 million. Covance actually reported earnings of $0.98 per share on sales of $671.0 million, missing EPS estimates by $0.00 and beating revenue estimates by $19.9 million. Since the company's report, shares of Covance have fallen from $100.57 to $100.30, representing a loss of 0.3% in the past 14 days.
CVD: 103.73 (+0.02)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Covance, Inc. in Connection with the Sale of the Company
Business Wire - Mon Nov 17, 6:00AM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Covance, Inc. ("Covance" or the "Company" (NYSE:CVD) relating to the proposed acquisition by Laboratory Corporation of America Holdings. ("LabCorp" .
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
Covance Shares Up 25.5% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Thu Nov 13, 10:07AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.08. In approximately 3 weeks, Covance has returned 25.53% as of today's recent price of $100.53.
CVD: 103.73 (+0.02)
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 56.48 (+0.57), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72), CVD: 103.73 (+0.02)
Merger Arbitrage Mondays - November 10, 2014
Asif Suria - Seeking Alpha - Mon Nov 10, 11:24AM CST
Merger Activity increased last week with six new mergers announced and one deal closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
ESYS: 17.30 (unch), HBNK: 20.95 (+0.10), LNN: 85.70 (-0.22), BHLB: 26.32 (-0.03), SAPE: 24.81 (-0.01), XWES: 5.49 (-0.01), ENOC: 15.37 (+0.03), LH: 107.69 (+0.56), STL: 14.14 (-0.04), HVB: 26.73 (-0.15), BAGL: 20.23 (-0.01), CVD: 103.73 (+0.02)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Covance Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Nov 10, 6:43AM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Covance Inc. ("Covance" or the "Company" (NYSE:CVD) relating to the proposed buyout of the Company by Laboratory Corp. of America Holdings ("LabCorp" .
CVD: 103.73 (+0.02)
Downgrade Alert for Covance (CVD)
Comtex SmarTrend(R) - Fri Nov 07, 6:54AM CST
Covance (NYSE:CVD) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $101.10 on volume of 1.3 million shares, above average daily volume of 1.0 million. Covance Inc. is a contract research organization providing a wide range of integrated product development services on a worldwide basis. The Company's customers include the pharmaceutical, biotechnology, and medical device industries. Covance also provides health economics and outcomes services, as well as laboratory testing services.
CVD: 103.73 (+0.02)
Uptrend Call Working As Covance Stock Rises 29.5% (CVD)
Comtex SmarTrend(R) - Mon Dec 22, 9:14AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.08. In approximately 2 months, Covance has returned 29.49% as of today's recent price of $103.70.
CVD: 103.73 (+0.02)
Hart-Scott-Rodino Waiting Period Expires for LabCorp Acquisition of Covance
Business Wire - Tue Dec 16, 7:45AM CST
Laboratory Corporation of America(R) Holdings (LabCorp(R)) (NYSE: LH) and Covance Inc. (Covance) (NYSE: CVD) jointly announced today the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with the previously announced merger agreement under which LabCorp will acquire all of the outstanding common stock of Covance. The waiting period expired on Monday, December 15.
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
27.3% Return Seen to Date on SmarTrend Covance Call (CVD)
Comtex SmarTrend(R) - Fri Dec 12, 4:46PM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 2 months, Covance has returned 27.29% as of today's recent price of $101.94.
CVD: 103.73 (+0.02)
COVANCE INC. SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation Of Buyout
Business Wire - Fri Dec 12, 12:08PM CST
Rigrodsky & Long, P.A.:
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
LabCorp Buys DNA Testing Firm, Expands Forensics Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Dec 08, 1:00PM CST
Management at LabCorp (LH) is optimistic that this acquisition will enhance the company's range of forensics and DNA identification testing services.
ABC: 91.60 (+0.18), LH: 107.69 (+0.56), MMSI: 17.17 (+0.01), CVD: 103.73 (+0.02)
Investor Lawsuit Against Takeover of Covance Inc. (CVD) Announced by Shareholders Foundation
GlobeNewswire - Mon Dec 08, 9:15AM CST
The Shareholders Foundation, Inc. announces that an investor, who currently holds shares of Covance Inc. (CVD), filed a lawsuit in effort to stop the proposed takeover of Covance Inc. by Laboratory Corporation of America Holdings for a value of approximately $105.12 per CVD share.
LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
Life Sciences Tools and Services Equities Coverage - Agilent Technologies, Thermo Fisher Scientific, Bruker, Quintiles Transnational, and Covance
PR Newswire - Mon Dec 08, 8:05AM CST
Investor-Edge has initiated coverage on the following equities: Agilent Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), Bruker Corporation (NASDAQ: BRKR), Quintiles Transnational Holdings Inc. (NYSE: Q), and Covance Inc. (NYSE: CVD). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Friday, December 05, 2014, ended on a positive note as the Dow Jones Industrial Average finished at 17,958.79, up 0.33% and the NASDAQ Composite closed at 4,780.76, up 0.24%. The S&P 500 finished the session 0.17% higher at 2,075.37. During the trading session, five out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 817.34, up 0.77%, with the index advancing 10.21% in the previous three months. Register for your complimentary reports on these five stocks at:
Q: 59.48 (+0.01), TMO: 126.79 (+0.13), A: 41.13 (-0.24), BRKR: 19.50 (+0.09), CVD: 103.73 (+0.02)
Watch Out: Barbarians At The Gate For Covance (CVD)
at The Street - Fri Nov 28, 9:15AM CST
Trade-Ideas LLC identified Covance (CVD) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
CVD: 103.73 (+0.02)
Covance Has Returned 25.9% Since SmarTrend Recommendation (CVD)
Comtex SmarTrend(R) - Thu Nov 20, 11:02AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.09. In approximately 4 weeks, Covance has returned 25.94% as of today's recent price of $100.86.
CVD: 103.73 (+0.02)
Morgan & Morgan Announces That It is Investigating the Sale of Covance, Inc. ? CVD
PR Newswire - Thu Nov 20, 10:15AM CST
Morgan & Morgan announces that it is investigating potential claims against the Board of Directors of Covance, Inc. ("Covance" or the "Company"
(NYSE: CVD) relating to the proposed acquisition by Laboratory Corporation of America Holdings ("LabCorp" . LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
Covance (CVD) Sellout Decision to LabCorp: A Strategic Fit? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 18, 3:10PM CST
On Nov 18, we issued an updated research report on Covance Inc. (CVD).
Q: 59.48 (+0.01), LH: 107.69 (+0.56), SNY: 46.35 (+0.50), CVD: 103.73 (+0.02)
Earnings Look Back: Covance Is Down 0.3% Since Reporting Quarterly Results 2 Weeks Ago (CVD)
Comtex SmarTrend(R) - Mon Nov 17, 8:51AM CST
Two weeks ago on November 3rd, 2014 Covance (NYSE:CVD) reported earnings and analysts, on average, expected earnings of $0.98 on sales of $651.1 million. Covance actually reported earnings of $0.98 per share on sales of $671.0 million, missing EPS estimates by $0.00 and beating revenue estimates by $19.9 million. Since the company's report, shares of Covance have fallen from $100.57 to $100.30, representing a loss of 0.3% in the past 14 days.
CVD: 103.73 (+0.02)
SHAREHOLDER ALERT: Brodsky & Smith, LLC Announces Investigation of Covance, Inc. in Connection with the Sale of the Company
Business Wire - Mon Nov 17, 6:00AM CST
Law office of Brodsky & Smith, LLC announces that it is investigating potential claims against the Board of Directors of Covance, Inc. ("Covance" or the "Company"
(NYSE:CVD) relating to the proposed acquisition by Laboratory Corporation of America Holdings. ("LabCorp" . LH: 107.69 (+0.56), CVD: 103.73 (+0.02)
Covance Shares Up 25.5% Since SmarTrend's Buy Recommendation (CVD)
Comtex SmarTrend(R) - Thu Nov 13, 10:07AM CST
SmarTrend identified an Uptrend for Covance (NYSE:CVD) on October 22nd, 2014 at $80.08. In approximately 3 weeks, Covance has returned 25.53% as of today's recent price of $100.53.
CVD: 103.73 (+0.02)
Regulatory Affairs Outsourcing Market - Global Industry Analysis 2014 - 2020
M2 - Tue Nov 11, 9:27AM CST
Research and Markets (http://www.researchandmarkets.com/research/8t6h79/regulatory) has announced the addition of the "Regulatory Affairs Outsourcing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020" report to their offering. The global regulatory affairs outsourcing market is segmented by services into regulatory affairs; clinical trial applications and product registrations; regulatory writing and publishing; regulatory consulting and legal representation; and others (post approval maintenance, reimbursement consulting etc.). Regulatory writing and publishing services accounted for the largest share of more than 40% of the overall regulatory affairs outsourcing market in 2013 and is expected to maintain its lead during the forecast period through 2014 to 2020. Factors that have contributed towards the large market size of the regulatory writing and publishing services are increasing need for user/reviewer friendly and complete drug application submissions, and sound knowledge for drug development services. Additionally, a well-written clinical study report (CSR) can help in adding a lot of value in the final production of clinical trial documentation, thereby complying with stringent regulatory requirements of the drug development process. The regulatory consulting and legal representation services segment is also estimated to grow at an approximate CAGR of above 14%. The major driving factors for the rapid growth of this segment are growing demand of drug manufacturing companies for product safety and efficacy evaluations. Furthermore, the need of various pharmaceutical companies to minimize business impacts such as product recalls and loss of sales, and ensure global environmental compliance would also propel the growth of the regulatory consulting and legal representation services segment. Currently, the regulatory affairs outsourcing market is fragmented due to the involvement of several established and emerging contract research organizations. Some of the major players operating in the global regulatory affairs outsourcing market are Charles River Laboratories International, Inc., Covance Group Ltd., Parexel International Corporation, WuXi AppTec, Quintiles Transnational Holdings, Inc., Medpace, Inc., Promedica International, Clinilabs, Inc., Accell Clinical Research, LLC, Criterium, Inc., ICON plc and Pharmaceutical Product Development. Key Topics Covered: Chapter 1 Introduction Chapter 2 Executive Summary Chapter 3 Global Regulatory Affairs Outsourcing Market Overview Chapter 4 Global Regulatory Affairs Outsourcing Market, by Services Chapter 5 Global Regulatory Affairs Outsourcing Market, by Geography Chapter 6 Recommendations Chapter 7 Company Profiles - Accell Clinical Research, LLC - Charles River Laboratories International, Inc. - Clinilabs, Inc. - Covance, Inc. - Criterium, Inc. - ICON plc - Medpace, Inc. - PAREXEL International Corporation - PRA International, Inc. - Pharmaceutical Product Development, LLC - Promedica International - Quintiles Transnational Corporation - WuXi AppTec For more information visit http://www.researchandmarkets.com/research/8t6h79/regulatory
PRXL: 56.48 (+0.57), CRL: 63.59 (+0.33), ICLR: 52.66 (+0.72), CVD: 103.73 (+0.02)
Merger Arbitrage Mondays - November 10, 2014
Asif Suria - Seeking Alpha - Mon Nov 10, 11:24AM CST
Merger Activity increased last week with six new mergers announced and one deal closing. You can find all the active deals listed below in our Merger Arbitrage Tool that automatically updates itself during market hours. Deal Statistics: ...
ESYS: 17.30 (unch), HBNK: 20.95 (+0.10), LNN: 85.70 (-0.22), BHLB: 26.32 (-0.03), SAPE: 24.81 (-0.01), XWES: 5.49 (-0.01), ENOC: 15.37 (+0.03), LH: 107.69 (+0.56), STL: 14.14 (-0.04), HVB: 26.73 (-0.15), BAGL: 20.23 (-0.01), CVD: 103.73 (+0.02)
SHAREHOLDER ALERT: Brower Piven Launches An Investigation Into The Proposed Sale Of Covance Inc. And Encourages Investors To Contact The Firm For Additional Information
Business Wire - Mon Nov 10, 6:43AM CST
The securities litigation law firm of Brower Piven, A Professional Corporation, has commenced an investigation into possible breaches of fiduciary duty and other violations of state law by the Board of Directors of Covance Inc. ("Covance" or the "Company"
(NYSE:CVD) relating to the proposed buyout of the Company by Laboratory Corp. of America Holdings ("LabCorp" . CVD: 103.73 (+0.02)
Downgrade Alert for Covance (CVD)
Comtex SmarTrend(R) - Fri Nov 07, 6:54AM CST
Covance (NYSE:CVD) was downgraded from Buy to Hold at Jefferies today. The stock closed yesterday at $101.10 on volume of 1.3 million shares, above average daily volume of 1.0 million. Covance Inc. is a contract research organization providing a wide range of integrated product development services on a worldwide basis. The Company's customers include the pharmaceutical, biotechnology, and medical device industries. Covance also provides health economics and outcomes services, as well as laboratory testing services.
CVD: 103.73 (+0.02)
